Rhinomed Ltd (ASX: RNO) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Rhinomed Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $74.87 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 253.81 million
Earnings per share -0.032
Dividend per share N/A
Year To Date Return 78.13%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Rhinomed Ltd (ASX: RNO)
Latest News

RNO ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Rhinomed Ltd

Formerly Consegna Group Limited (CGP), 15/11/2013.

RNO Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
01 Dec 2021 $0.29 $0.01 3.64% 586,744 $0.29 $0.33 $0.28
30 Nov 2021 $0.28 $0.02 7.84% 100,497 $0.26 $0.28 $0.26
29 Nov 2021 $0.26 $-0.02 -7.41% 31,065 $0.27 $0.27 $0.26
26 Nov 2021 $0.27 $0.02 7.84% 132,760 $0.26 $0.28 $0.26
25 Nov 2021 $0.26 $0.01 4.00% 24,902 $0.25 $0.26 $0.25
24 Nov 2021 $0.25 $0.00 0.00% 4,530 $0.25 $0.25 $0.25
23 Nov 2021 $0.25 $0.00 0.00% 62,730 $0.25 $0.25 $0.25
22 Nov 2021 $0.25 $0.01 4.17% 152,639 $0.23 $0.25 $0.23
19 Nov 2021 $0.24 $-0.02 -7.69% 152,405 $0.28 $0.28 $0.24
18 Nov 2021 $0.26 $-0.02 -7.27% 38,485 $0.28 $0.28 $0.26
17 Nov 2021 $0.28 $0.05 22.22% 401,741 $0.24 $0.28 $0.24
16 Nov 2021 $0.23 $-0.02 -8.33% 87,550 $0.24 $0.24 $0.23
15 Nov 2021 $0.24 $-0.03 -11.32% 466,906 $0.25 $0.25 $0.22
12 Nov 2021 $0.27 $0.03 12.50% 143,269 $0.24 $0.27 $0.24
11 Nov 2021 $0.24 $-0.01 -4.08% 147,749 $0.26 $0.26 $0.24
10 Nov 2021 $0.25 $-0.03 -11.11% 280,436 $0.26 $0.26 $0.24
09 Nov 2021 $0.27 $0.03 12.24% 143,747 $0.25 $0.28 $0.25
08 Nov 2021 $0.25 $-0.05 -17.24% 688,003 $0.29 $0.29 $0.24
05 Nov 2021 $0.29 $-0.01 -3.39% 70,403 $0.29 $0.29 $0.29
04 Nov 2021 $0.30 $0.00 0.00% 52,406 $0.30 $0.30 $0.30
03 Nov 2021 $0.30 $0.01 3.45% 227,603 $0.29 $0.30 $0.29
02 Nov 2021 $0.29 $0.00 0.00% 84,106 $0.30 $0.30 $0.29

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
02 Jul 2021 John McBain Buy 487 $77,107
On-market trade.
24 Jun 2021 John McBain Buy 506 $75,959
On-market trade.
15 Mar 2021 Michael Johnson Issued 12 $10
Off-market trade.
01 Feb 2021 Ronald (Ron) Dewhurst Buy 250 $31,250
On-market trade.
23 Dec 2020 Michael Johnson Issued 12 $2,093,925
Issue of options. As per announcement on 23/12/2020.
21 Dec 2020 Ronald (Ron) Dewhurst Buy 1 $180,000
On-market trade.
14 Dec 2020 Michael Johnson Buy 16 $3,015
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Michael Johnson Chief Executive OfficerManaging Director Feb 2013
Mr Johnson is a director of Cogentum. Over the past 20 years, Mr Johnson has worked in and for a spectrum of companies from ASX 300 through to start-up companies in life sciences, cleantech, finance services, energy and utilities, manufacturing, marketing and communication, automotive, and consumer packaged goods. His recent work has had focus on helping companies implement technology platforms and achieve growth through business model innovation. Mr Johnson has been a Principal at two consulting firms where he was to advise on innovation and compete in regulated industries. Before that, he held roles within some of the world's marketing and communication firms where he launched a number of products and brands.
Mr Ronald (Ron) Richard Dewhurst Non-Executive ChairmanNon-Executive Director Dec 2015
Mr Dewhurst has had spend 40 years in the investment banking and asset management industries, covering Australia, Asia, Europe and United States of America. He was formerly Head of Americas for J P Morgan Asset Management, and Senior Executive Vice President and Head of Investment Managers for Legg Mason Inc. based in the United States. He is currently a Director of Sprott Inc (Since 9 January 2017).
Mr Brent Scrimshaw Non-Executive Director Feb 2014
Mr Scrimshaw brings a understanding of the requirements of building brands and businesses around the world. During a 19 year career with Nike Inc. where he held the position of Vice President and Chief Executive of Western Europe amongst other leadership roles and was a Member of the leadership team where he was in charge for many of Nike's growth and brand strategies.
Dr Eric Knight Non-Executive Director Feb 2014
Dr Knight brings experience in corporate strategy and management, having previously worked for Boston Consulting Group, and subsequently serving as Professor of Strategic Management at University of Sydney and recently as Professor of Management and Executive Dean of Macquarie Business School. Dr Knight is recognised internationally for his work on design-led strategy.
Professor John McBain Non-Executive Director May 2021
Assoc Prof McBain has knowledge and experience in the medical field. Assoc Prof McBain is the former Head of Reproductive Services at The Royal Women's Hospital in Melbourne, Australia. He is also the former President of the Fertility Society of Australia, and was a founder of Melbourne IVF, now Virtus Health (ASX:VRT). Assoc Prof McBain served as a Director of Melbourne IVF and subsequently as a Director of Virtus Health prior to its listing on the ASX. He is currently a Non Executive Director of AP Ventures.
Mr Sean Slattery Chief Financial OfficerCompany Secretary Mar 2020
-
Sean Slattery Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Merrill Lynch (Australia) Nominees Pty Limited 105,869,675 41.71%
Thirty-Fifth Celebration Pty Ltd <Jc Mcbain Super Fund A/C> 13,951,657 5.50%
BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient Drp> 10,854,547 4.28%
Fifty Second Celebration Pty Ltd <Mcbain Family A/C> 9,482,830 3.74%
Kroy Wen Pty Ltd 7,565,320 2.98%
Citicorp Nominees Pty Limited 7,009,312 2.76%
Kroy Wen Pty Ltd <Dewhurst Super Fund A/C> 5,684,680 2.24%
HSBC Custody Nominees (Australia) Limited GSCO ECA 5,383,317 2.12%
UBS Nominees Pty Ltd 3,753,476 1.48%
HSBC Custody Nominees (Australia) Limited A/C 2 3,090,275 1.22%
Mutual Trust Pty Ltd 3,000,000 1.18%
Kensington Capital Management Pty Ltd 2,800,000 1.10%
Argus Nominees Pty Ltd <The Halstead Super Fund A/C> 2,225,285 0.88%
Abingdon Nominees Pty Ltd <Abingdon Noms Invest A/C> 2,200,000 0.87%
J P Morgan Nominees Australia Pty Limited 1,942,300 0.77%
Jasforce Pty Ltd 1,514,572 0.60%
Ashlaw Pty Limited <Whitehead Super Fund A/C> 1,500,000 0.59%
HSBC Custody Nominees (Australia) Limited 1,265,441 0.50%
Ken Siebel 1,249,929 0.49%
Hishenk Pty Ltd 1,100,000 0.43%

Profile

since

Note